

The Importance of Blood  
Culture Contamination as a  
Metric for Hospital Rate  
Improvement  
Program (HRIP)

# What if one practice change could...\*

Empower Hospital Staff

Provided Patient Satisfaction and Quality Outcomes With Better Equitable Care and Reduced Costs


Enable Reimbursement for Services Provided



- ✓ Reduce unnecessary/prolonged antibiotic treatment
- ✓ Reduce the risk of *C.difficile*, MDROs, AKIs
- ✓ Reduce false-positive CLABSIs and MRSA
- ✓ Reduce unnecessary lab ID events
- ✓ Reduce unnecessary LOS and associated HAIs/HACs
- ✓ Reduce in-patient mortality
- ✓ Help meet CDC and The Joint Commission Antibiotic Stewardship Guidelines and CMS Star Ratings and mitigate BCC which CDC: calls a **“Patient Safety Event”**
- ✓ Help meet Magnet Requirements for Global Issues, Structural Empowerment, Transformational Leadership, New Knowledge Innovations and Improvement, Exemplary Professional Practice and Exceptional Empirical Outcomes
- ✓ Reduce laboratory and nursing labor
- ✓ Increase bed availability and throughput. NQF estimates **1,000,000 bed days** would open nationally if blood cultures were accurate
- ✓ Save the typical 250-400-bed hospital \$1.9M annually (not inclusive of mitigation of FP CLABSIs, FP MRSA and CDI)

Reducing blood culture contamination achieves all

# The Purpose of Blood Cultures. \*



## Confirm

the presence of microorganisms  
in the bloodstream




## Identify

the microbial etiology of the  
bloodstream infection



## Help

determine the source of infection  
(e.g., endocarditis)



## Provide

an organism for susceptibility testing  
and optimization of antimicrobial  
therapy

# Blood Culture Definitions \*


- Blood culture contamination (BCC) is defined as the recovery of **normal skin flora (common commensal)** from a **single blood culture set when two sets are obtained**
- Culture is defined as a specimen of blood that is submitted for bacterial or fungal culture. **This is irrespective of the number of bottles or tubes into which the specimen is divided.**
- A BCC rate represents **common commensal organism occurrence in one set of blood cultures out of two sets obtained**
- **Blood Culture Set:** the combination of blood culture bottles or tubes **into which a single blood specimen is inoculated**
- **Required volume is essential and assumed**



# Identity of the Organism


- Bates et al. found that the identity of the organism was the most important predictor for differentiating contaminated blood culture results from results indicating bacteremia
- **Common Commensal Organisms** or Probable Contaminants:
  - Coagulase-negative staphylococci (CoNS)
  - Propionibacterium spp. (Cutibacterium)
  - Aerococcus
  - Micrococcus
  - Bacillus spp. [not B. anthracis]
  - Corynebacterium spp. [diphtheroids]
  - Alpha-hemolytic streptococci

“These organisms may be considered contaminants unless recovered from multiple Blood cultures obtained in sequence, in which case, careful assessment of patients and additional laboratory information is required in defining significance (or lack thereof)” Doern




# Identity of the Organism. \*

- **Non-Common Commensal Organisms**  
(Usually a True Bacteremia or Fungemia)
  - Enterococcus
  - VRE
  - MRSA
  - Candida
  - E.coli
- Any organism NOT found on the NHSN Common Commensal list\* is considered a recognized pathogen for NHSN reporting purposes




# Test Results From Blood Cultures are Frequently Wrong \*

## ALL BLOOD CULTURES




## POSITIVE BLOOD CULTURES



False positives are a *preventable error* and can lead to a misdiagnosis of sepsis

<sup>1</sup>Zwang O, Albert RK. Analysis of strategies to improve cost effectiveness of blood cultures. J Hosp Med. 2006;1(5):272-6. doi:10.1002/jhm.115.


# False-positive blood cultures increase many harmful patient safety risks and CDC calls contaminated blood cultures a patient safety event. \*





# CMS National Quality Strategy Goals

The Eight Goals of the CMS National Quality Strategy are Organized into Four Priority Areas:



# AKI and Health Equity

“AKI is the **most clinically significant** adverse drug reaction reported with antibiotics, and **risk may be as high as 36%**.”

**Results: University of Arkansas; ICHE** “The patients most at risk for contamination were of older age, black race, higher BMI, and had comorbidities such as CHF, COPD, and paralysis. **Black patients were disproportionately at increased risk for blood-culture contamination (aOR, 1.32; 95% CI, 1.15–1.51), whereas white patients demonstrated a protective trend.**”


After controlling for age, race, BMI, comorbidities, and sepsis **blood-culture contamination increased... Acute kidney injury 40% higher risk**

***New IPPS/ e-Quality Reporting 2025 AKI Adding 15 new health equity categorizations for FY2024 payment impacts. Secondary to Equitable Care and higher incidence of AKI in Black hospitalized patients***

“Hospitals that fail to submit quality data or to meet all Hospital IQR Program requirements are subject to a one-fourth reduction in their Annual Payment Update under the IPPS.


Hospital Harm — Acute Kidney Injury eCQM, with inclusion in the eCQM measure set beginning with the CY 2025 reporting period/FY 2027 payment determination

CMS believes the adoption of the Hospital Harm-AKI and Hospital Harm-PI eCQMs will support CMS’ goal of advancing health equity. AKI is more common in Black hospitalized patients than non-Black patients”



# BSI Causation Secondary to Broad-Spectrum Antibiotics

- Prolonged **Vancomycin and Zosyn** leads to a **36-40%** risk of **AKI**<sup>1</sup>
- **AKI** can lead to **hemodialysis (30%)**
- Adults on dialysis are **100 times** more likely to have a **Staph Bloodstream Infection**<sup>2</sup>



# Risk of In-Patient Mortality Increases 74% Due to Blood Culture Contamination



**Significant, near doubling (8% vs 4.6%) of in-patient mortality rate for patients that had contaminated blood cultures vs. the true negative blood culture control group”**



Infection Control & Hospital Epidemiology (2022), 43, 291–297  
doi:10.1017/ice.2021.111

Original Article

### Risk factors and clinical outcomes associated with blood culture contamination

Justin M. Klucher BS<sup>1</sup>, Kevin Davis MD<sup>2</sup>, Minmayee Lakkad MS<sup>3</sup>, Jacob T. Painter PharmD, PhD<sup>3</sup> and Ryan K. Dare MD, MS<sup>4</sup>

<sup>1</sup>College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, <sup>2</sup>Mery Hospital, Fort Smith, Arkansas, <sup>3</sup>Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences, Little Rock, Arkansas and <sup>4</sup>Division of Infectious Diseases, University of Arkansas for Medical Sciences, Little Rock, Arkansas

**Abstract**  
Objective. To determine patient-specific risk factors and clinical outcomes associated with contaminated blood cultures.  
Design. A single-center, retrospective case-control risk factor and clinical outcome analysis performed on inpatients with blood cultures collected in the emergency department, 2014–2018. Patients with contaminated blood cultures (cases) were compared to patients with negative blood cultures (controls).  
Setting. A 509-bed tertiary-care university hospital.  
Methods. Risk factors independently associated with blood-culture contamination were determined using multivariable logistic regression. The impacts of contamination on clinical outcomes were assessed using linear regression, logistic regression, and generalized linear model with  $\gamma$  log link.  
Results. Of 13,782 blood cultures, 1,504 (10.9%) true positives were excluded, leaving 1,012 (7.3%) cases and 11,266 (81.7%) controls. The following factors were independently associated with blood-culture contamination: increasing age (adjusted odds ratio [aOR], 1.01; 95% confidence interval [CI], 1.01–1.01), black race (aOR, 1.32; 95% CI, 1.15–1.51), increased body mass index (BMI) (aOR, 1.01; 95% CI, 1.00–1.02), chronic obstructive pulmonary disease (aOR, 1.16; 95% CI, 1.02–1.33), paralysis (aOR, 1.64; 95% CI, 1.26–2.14), and sepsis plus shock (aOR, 1.26; 95% CI, 1.07–1.49). After controlling for age, race, BMI, and sepsis, blood-culture contamination increased length of stay (LOS,  $\beta = 1.24 \pm 0.24$ ;  $P < .0001$ ), length of antibiotic treatment (LOT,  $\beta = 1.01 \pm 0.20$ ;  $P < .001$ ), hospital charges ( $\beta = 0.22 \pm 0.03$ ;  $P < .0001$ ), acute kidney injury (AKI) (aOR, 1.60; 95% CI, 1.40–1.83), echocardiogram orders (aOR, 1.51; 95% CI, 1.30–1.75) and in-hospital mortality (aOR, 1.69; 95% CI, 1.31–2.16).  
Conclusions. These unique risk factors identify high-risk individuals for blood-culture contamination. After controlling for confounders, contamination significantly increased LOS, LOT, hospital charges, AKI, echocardiograms, and in-hospital mortality.  
(Received 27 October 2020; accepted 4 February 2021; electronically published 26 April 2021)

Blood cultures are considered the gold standard for detecting bloodstream infections they facilitate prompt and directed antimicrobial therapy for patients with sepsis<sup>1–4</sup> However, false-positive blood culture results can lead to inappropriate clinical evaluation and treatment, leading to unnecessary patient risk.<sup>5–7</sup> Blood culture contamination with skin microflora is believed to be the primary cause of false-positive blood culture results however, needle contamination and collector contamination have also been implicated.<sup>2,8,9</sup> Reported institutional blood-culture contamination rates vary significantly, from 0.6% to 10%, and the Clinical Laboratory Standards Institute recommends that institutions strive to achieve a contamination rate < 3%.<sup>24</sup> Efforts to reduce blood-culture contamination include the use of dedicated phlebotomists, the use of diversion devices, and ensuring proper sterile technique when collecting cultures.<sup>2,5,10–16</sup>

Reported risk factors associated with blood-culture contamination include poor collection method, staff competency, increased patient age, presence of comorbidities, and patient illness severity.<sup>2,5–16</sup> However, most of the relevant studies are relatively small, are performed over short periods, or focus on provider-specific risk factors rather than patient-specific risk factors. Additionally, with the introduction of the Centers for Medicare and Medicaid Services sepsis core measure (SEP-1),<sup>17–21</sup> the practice of “code sepsis” in emergency departments to expedite blood culture collection is increasing. Although this intervention likely improves time to antibiotic administration, it may compromise sterile technique, which worsens contamination rates. Since the introduction of code sepsis at our institution, emergency-department blood-culture contamination rates have increased to > 6%.

Author for correspondence: Ryan K. Dare, Email: [RDare@uams.edu](mailto:RDare@uams.edu)  
Cite this article: Klucher JM, et al. (2022), Risk factors and clinical outcomes associated with blood culture contamination, Infection Control & Hospital Epidemiology, 43, 291–297, <https://doi.org/10.1017/ice.2021.111>

© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America.

<https://doi.org/10.1017/ice.2021.111> Published online by Cambridge University Press

SHEA


BRIDGE CITY PRESS

ist: Lona Mody

© CrossMark

# What is a False-Positive CLABSI?

- A False-Positive CLABSI is defined in the literature as meeting the NHSN Surveillance Definition of a CLABSI with little to no clinical manifestation of bacteremia/fungemia
- This usually occurs when a **non-common** commensal organism like VRE or Candida is picked up from the skin during a **peripheral venipuncture** for blood culture collection and grows out in one bottle. **Gram positive organisms. Required aerobic volume (3 bottles)**
- This is different than an unnecessarily reported CLABSI when there is a primary infection at another site and a culture was not obtained from the primary site or other studies completed to show origin of infection



# False-Positive CLABSI Reporting



**42%** of reported CLABSIs represented contaminants”<sup>1</sup>

**30%** of reported CLABSIs were suspected to represent blood culture contamination”<sup>2</sup>

**45%** of reported CLABSIs most likely represented contaminated blood cultures rather than true CLABSIs”<sup>3</sup>


<sup>1</sup>Tompkins, LS, et al. Getting to zero: impact of a device to reduce blood culture contamination and false-positive central line-associated blood stream infections. ICHE Sept. 2023

<sup>2</sup>Boyce JM, Nadeau J, Dumigan D, et al. Obtaining blood cultures by venipuncture versus from central lines: impact on blood culture contamination rates and potential effect on central line-associated bloodstream infection reporting. *Infect Control Hosp Epidemiol.* 2013;34(10):1042-7. doi:10.1086/673142.

<sup>3</sup>Shuman EK, Washer LL, Amdt JL, et al. Analysis of central line-associated bloodstream infections in the intensive care unit after implementation of central line bundles. *Infect Control Hosp Epidemiol.* 2010;31(5):551-3. doi:10.1086/652157.



Clinical  
Infectious  
Diseases



False-Positive CLABSI Reporting  
(CMS NHSN Surveillance Definition LCBI1)

# Our Two “Go To” Antibiotics for Sepsis

Vancomycin

- Implicated in the causation of CDI

Zosyn

- Implicated in the causation of CDI

Diagnostic Stewardship can help reduce both

Clinical  
Infectious  
Diseases

AJIC


American Journal of Infection Control

Official Publication of



# Agency for Healthcare Research and Quality

The Four Moments of Antibiotic Decision Making





# Hospitals report HACs to NHSN



- CAUTI
- SSI
- CLABSI
- *C. difficile*
- MRSA BSI




Significantly impacted by BC contamination (non-common & common commensal organisms)

- National SIR for CLABSIs increased 46% / 47% during COVID (24% 2020 average increase)  
(Q3/Q4 '20 vs. Q3/Q4 '19)<sup>1</sup> AND remained 7% higher than pandemic levels for 2021. 2022 had a 9% decrease still leaving us at a 22% average increase over pre-pandemic levels. **2023 had a 15% decrease and we remain 7% over pre-pandemic rates**
- National SIR for MRSA increased 23% / 34% during COVID (15% 2020 average increase)  
(Q3/Q4 '20 vs. Q3/Q4 '19)<sup>1</sup> AND remained 14% higher than pandemic levels for 2021. 2022 saw a 16% decrease still leaving us at an average 13% increase over pre-pandemic levels. **2023 had a 16% decrease making us finally below our pre-pandemic rates**
- **AKI started and HOB coming soon**

<sup>1</sup>Weiner-Lastinger LM, Pattabiraman V, Konnor RY, et al. The impact of coronavirus disease 2019 on healthcare-associated infections in 2020: summary of data reported to the NHSN. *Infect Control Hosp Epidemiol.* 2021;1-14. doi:10.1017/ice.2021.362.A39:B40.  
CDC 2023 HAI Progress Report

# HAC Penalty Calculation (example)



	Total Net <sup>1</sup> Revenue	Average Percent <sup>1</sup> of Payer Mix
 Medicare	\$398B	19.5%
 Medicaid	\$259B	12.7%
 Private/Self/Other	\$1.388T	67.9%


## Potential Penalty Calculation



Average Percent of Payer Mix	32.2%
Hospital Revenue	\$1,000,000,000
CMS Revenue	\$322,000,000
<b>Potential CMS Penalty (1.0%)</b>	<b>\$3,220,000</b>

<sup>1</sup>Definitive Healthcare's proprietary data on payer mix, March 2019

# Potential CMS Revenue Loss



Goal of ZERO blood culture contamination can help prevent up to 6% CMS revenue loss plus cost of initial care

\* Using 2015 AHRQ Data Published in 2017

AJIC 2024 <https://doi.org/10.1016/j.ajic.2024.07.014>  
CLABSI,CAUTI, SSI cost and LOS increased 150% 2019-2024

# CMS Star Ratings

- Measures across 5 Quality Areas into a Star Rating for each hospital
- Hospitals report to CMS via Inpatient and Outpatient Quality Reporting Program, Readmission Reduction Program, Hospital Acquired Condition, and VBP Program
- It is a weighted measure for each group
- Began July 2023
- First calculation July 2024
- These Star Ratings affect the hospital's Value Based Purchasing Score, HAC Score, Readmissions and IQR Score

# Measures and Weighting for Star Ratings

MRSA, CDI, CLABSI

All Cause Readmission Rate

Rating of who would recommend hospital to family and friends

Time in ED, those who left Without being seen, those who Received timely and effective care for Sepsis

Measure group	Weight used in calculation
Mortality	22%
Safety	22%
Readmission	22%
Patient Experience	22%
Timely & Effective Care	12%




# Solution:

Evidence Based Technique and Technology  
lead to Diagnostic Stewardship,  
Antimicrobial Stewardship and Quality  
Patient Outcomes

<b>Patient Selection</b>	Blood cultures should only be performed in patients with a reasonable likelihood of bacteremia/fungemia.
<b>Skin disinfection</b>	Use a CHG and alcohol-containing disinfectant to scrub the phlebotomy site; adhere to recommended scrub and dry times
<b>Blood Culture Bottle Top Disinfection</b>	Disinfect blood culture vial caps with alcohol for 15 seconds
<b>Consideration</b>	Leave an IPA or sterile pad on top of the BC bottle, to protect from environmental contaminants, until ready to inoculate with blood. IPA typically takes 5 seconds to dry
<b>Phlebotomy Site</b>	Don't draw blood cultures through indwelling vascular catheters unless the catheter is thought to be the source of infection. In that case, replace NC and draw via new NC, consider draw from each lumen. Do not waste, understand locking solution may interfere with results. Draw a second set from a peripheral venipuncture. Consider differential time to positivity. Send to lab within 2 hours, do not refrigerate sample
<b>Sets</b>	Always draw two sets from <b>different</b> sites. Always draw blood cultures first and prior to antibiotics
<b>Volume</b>	<b>Is the single most important factor for organism detection.</b> Draw volume per bottle IFU
<b>Standardized Kits</b>	Use of standardized kits and procedures has proven helpful in preventing contamination
<b>Phlebotomy Teams</b>	Educate and train individuals who perform blood cultures in aseptic technique
<b>Surveillance and Feedback</b>	Monitor blood culture contamination and provide data to individuals and patient care units
<b>Multidisciplinary Teams</b>	Sustained improvement in blood culture contamination is best achieved through a team approach.
<b>Initial Specimen Diversion Device</b>	Divert and discard > 1mL of initial sample. Use of ISDD has been shown to decrease contamination rates to less than 1%.

# Algorithm for bacterial blood cultures in nonneutropenic inpatients



Efficacy of using an algorithm Sept 2024 AJIC

Valeria Fabre et al. Does This Patient Need Blood Cultures? A Scoping Review of Indications for Blood Cultures in Adult Nonneutropenic Inpatients, *Clinical Infectious Diseases* 2020:71 September



Theophalus, R. Blood culture algorithm implementation in emergency department patients as a diagnostic stewardship intervention. *American Journal of Infection Prevention* May 2024

<https://doi.org/10.1016/j.ajic.2024.04.198>



# Evidence-Based Checklist for Adult Peripheral Blood Culture Collection Summary

## Look to Process Discovery Tool

- Utilize astute patient selection and check order.
- Identify and inform patient.
- Ensure environmental surfaces used are disinfected.
- Perform hand hygiene. Use aseptic non touch technique throughout entire process.
- Mask self and patient.
- Prepare to draw 2-3 sets of blood cultures within a short time frame. Each set to be drawn from a different site. Avoid single bottle sets and drawing more than 3 sets within a 24 hour period if indicated.
- Select a site opposite of any infusion or if not possible, distal to any infusion. The cubital fossa is a preferred site.
- Each set to be drawn from a different venipuncture or new start PIV and include one aerobic and one anaerobic bottle per policy.
- Mark bottles for fill volume and fill to that volume. Most manufacturers require 8-10mL per bottle.
- Disinfect venipuncture site with 2% Chlorhexidine and Alcohol product per manufacturer's directions.
- Remove bottle cap and scrub bottle septum with a 70% alcohol prep pad for a full 15 seconds.
- Consider covering bottle top with a sterile 1x1 or new alcohol prep pad and leave on until placing bottle in adapter.
- Select site and apply single patient tourniquet - validate site, then remove tourniquet and don clean gloves.
- Consideration: Sterile set up with sterile barrier, gloves and tourniquet. Don gloves, apply barrier, apply tourniquet and perform venipuncture procedure.
- Draw blood cultures first, making sure to draw the recommended volume into the aerobic bottle first.
- Divert and sequester initial milliliter of blood drawn for culture into a sterile receptacle to minimize the risk of contamination. Use of ISDDs have been shown to reduce blood culture contamination rates to less than 1%.
- Finish procedure, applying a sterile dressing and light pressure after completing blood draw. Place sharps in sharp's disposal containers compliant with local and federal regulations.
- Label bottles in presence of the patient, agitate gently per manufacturer's instructions, and place in biohazard bag and send to lab immediately.

# Training and Education on “Best Practices” and/or Phlebotomists Alone

**Will Not** Solve the Problem:

**\*KYHA Successes and Process Discovery Tool**


**Controllable**



## **Human Factor(s)**


Risk of contamination during assembly, preparation of supplies and skin prep

**Uncontrollable**



## **Skin Flora**

You can disinfect but not sterilize the skin. Up to 20% of skin flora remains viable in the keratin layer of the skin even after skin prep<sup>1</sup>



## **Skin Plug and Fragments**

(uncontrollable factors) will enter the culture specimen bottle and commonly will contain viable microorganisms (when present)

Active diversion of the **initial 1.5-2.0 mL of blood** using a closed system (Initial Specimen Diversion Device<sup>®</sup>) has been clinically proven to significantly reduce blood culture contamination<sup>2,3</sup>

# ISDD: Nine Peer-Reviewed Published Studies



**Clinical Infectious Diseases**  
2017 (July)

**Original Manuscript**  
**MAJOR ARTICLE**

### Reduction in Blood Culture Contamination Through Use of Initial Specimen Diversion Device

Max A. Anton, MD, PhD, et al.

**Abstract.** Blood culture contamination is a clinically significant problem in patient blood culture testing.

**Methods.** The prospective, controlled trial was conducted in a tertiary care hospital. The study was designed to evaluate the impact of a single-site diversion device on blood culture contamination. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of a single-site diversion device on blood culture contamination. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of a single-site diversion device on blood culture contamination.

**Results.** The study was designed to evaluate the impact of a single-site diversion device on blood culture contamination. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of a single-site diversion device on blood culture contamination. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of a single-site diversion device on blood culture contamination.

**Conclusion.** The use of a single-site diversion device significantly reduced blood culture contamination. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of a single-site diversion device on blood culture contamination. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of a single-site diversion device on blood culture contamination.



**Journal for Emergency Nursing**  
2018 (Nov)

**Practical Improvement**

### EFFECTIVENESS OF A NOVEL SPECIMEN COLLECTION SYSTEM IN REDUCING BLOOD CULTURE CONTAMINATION RATES

Authors: Kelly G. McNeil, MD, PhD, et al.

**Abstract.** Blood culture contamination is a clinically significant problem in patient blood culture testing. The study was designed to evaluate the impact of a novel specimen collection system on blood culture contamination rates.

**Methods.** The study was designed to evaluate the impact of a novel specimen collection system on blood culture contamination rates. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of a novel specimen collection system on blood culture contamination rates.

**Results.** The study was designed to evaluate the impact of a novel specimen collection system on blood culture contamination rates. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of a novel specimen collection system on blood culture contamination rates.

**Conclusion.** The use of a novel specimen collection system significantly reduced blood culture contamination rates. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of a novel specimen collection system on blood culture contamination rates.



**Journal of Clinical Microbiology**  
2019 (Jan)

**Estimated Clinical and Economic Impact through Use of a Novel Blood Collection Device to Reduce Blood Culture Contamination in the Emergency Department: A Cost-Benefit Analysis**

Authors: Kelly G. McNeil, MD, PhD, et al.

**Abstract.** Blood culture contamination is a clinically significant problem in patient blood culture testing. The study was designed to evaluate the impact of a novel blood collection device on blood culture contamination rates and economic impact.

**Methods.** The study was designed to evaluate the impact of a novel blood collection device on blood culture contamination rates and economic impact. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of a novel blood collection device on blood culture contamination rates and economic impact.

**Results.** The study was designed to evaluate the impact of a novel blood collection device on blood culture contamination rates and economic impact. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of a novel blood collection device on blood culture contamination rates and economic impact.

**Conclusion.** The use of a novel blood collection device significantly reduced blood culture contamination rates and economic impact. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of a novel blood collection device on blood culture contamination rates and economic impact.



**American Journal Infection Control**  
2019 (Jan)

**ARTICLE IN PRESS**

### Reducing blood culture contamination using an initial specimen diversion device

Authors: Kelly G. McNeil, MD, PhD, et al.

**Abstract.** Blood culture contamination is a clinically significant problem in patient blood culture testing. The study was designed to evaluate the impact of an initial specimen diversion device on blood culture contamination rates.

**Methods.** The study was designed to evaluate the impact of an initial specimen diversion device on blood culture contamination rates. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of an initial specimen diversion device on blood culture contamination rates.

**Results.** The study was designed to evaluate the impact of an initial specimen diversion device on blood culture contamination rates. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of an initial specimen diversion device on blood culture contamination rates.

**Conclusion.** The use of an initial specimen diversion device significantly reduced blood culture contamination rates. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of an initial specimen diversion device on blood culture contamination rates.



**Journal of Hospital Infection**  
2019 (Mar)

**Model to evaluate the impact of hospital-based interventions targeting false-positive blood cultures on economic and clinical outcomes**

Authors: Kelly G. McNeil, MD, PhD, et al.

**Abstract.** Blood culture contamination is a clinically significant problem in patient blood culture testing. The study was designed to evaluate the impact of hospital-based interventions on economic and clinical outcomes.

**Methods.** The study was designed to evaluate the impact of hospital-based interventions on economic and clinical outcomes. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of hospital-based interventions on economic and clinical outcomes.

**Results.** The study was designed to evaluate the impact of hospital-based interventions on economic and clinical outcomes. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of hospital-based interventions on economic and clinical outcomes.

**Conclusion.** The use of hospital-based interventions significantly reduced economic and clinical outcomes. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of hospital-based interventions on economic and clinical outcomes.



**Journal for Emergency Nursing**  
2021 (Mar)

**Practical Improvement**

### ASYNCHRONOUS TESTING OF 2 SPECIMEN-DIVERSION DEVICES TO REDUCE BLOOD CULTURE CONTAMINATION: A SINGLE-SITE PRODUCT SUPPLY QUALITY IMPROVEMENT PROJECT

Authors: Max A. Anton, MD, PhD, et al.

**Abstract.** Blood culture contamination is a clinically significant problem in patient blood culture testing. The study was designed to evaluate the impact of asynchronous testing of two specimen-diversion devices on blood culture contamination rates.

**Methods.** The study was designed to evaluate the impact of asynchronous testing of two specimen-diversion devices on blood culture contamination rates. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of asynchronous testing of two specimen-diversion devices on blood culture contamination rates.

**Results.** The study was designed to evaluate the impact of asynchronous testing of two specimen-diversion devices on blood culture contamination rates. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of asynchronous testing of two specimen-diversion devices on blood culture contamination rates.

**Conclusion.** The use of asynchronous testing of two specimen-diversion devices significantly reduced blood culture contamination rates. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of asynchronous testing of two specimen-diversion devices on blood culture contamination rates.



**Journal of Hospital Infection**  
2021 (Nov)

**Initial Specimen Diversion Device<sup>®</sup> reduces blood culture contamination and vancomycin use in academic medical centre**

Authors: L.E. Nielsen, K. Nguyen, C.K. Wahl, J.L. Husg, D. Chang, E.P. Agor, et al.

**Abstract.** Blood culture contamination is a clinically significant problem in patient blood culture testing. The study was designed to evaluate the impact of an initial specimen diversion device on blood culture contamination rates and vancomycin use.

**Methods.** The study was designed to evaluate the impact of an initial specimen diversion device on blood culture contamination rates and vancomycin use. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of an initial specimen diversion device on blood culture contamination rates and vancomycin use.

**Results.** The study was designed to evaluate the impact of an initial specimen diversion device on blood culture contamination rates and vancomycin use. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of an initial specimen diversion device on blood culture contamination rates and vancomycin use.

**Conclusion.** The use of an initial specimen diversion device significantly reduced blood culture contamination rates and vancomycin use. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of an initial specimen diversion device on blood culture contamination rates and vancomycin use.



**American Journal Medical Quality**  
2022 (April)

**Initial Specimen Diversion Device Utilization Mitigates Blood Culture Contamination Across Regional Community Hospital and Acute Care Facility**

Authors: Max A. Anton, MD, PhD, et al.

**Abstract.** Blood culture contamination is a clinically significant problem in patient blood culture testing. The study was designed to evaluate the impact of an initial specimen diversion device on blood culture contamination rates across a regional community hospital and an acute care facility.

**Methods.** The study was designed to evaluate the impact of an initial specimen diversion device on blood culture contamination rates across a regional community hospital and an acute care facility. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of an initial specimen diversion device on blood culture contamination rates across a regional community hospital and an acute care facility.

**Results.** The study was designed to evaluate the impact of an initial specimen diversion device on blood culture contamination rates across a regional community hospital and an acute care facility. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of an initial specimen diversion device on blood culture contamination rates across a regional community hospital and an acute care facility.

**Conclusion.** The use of an initial specimen diversion device significantly reduced blood culture contamination rates across a regional community hospital and an acute care facility. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of an initial specimen diversion device on blood culture contamination rates across a regional community hospital and an acute care facility.



**Infection Control & Hospital Epidemiology**  
2022 (December)

**Getting to zero: Impact of a device to reduce blood culture contamination and false-positive central-line-associated bloodstream infections**

Authors: Kelly G. McNeil, MD, PhD, et al.


**Abstract.** Blood culture contamination is a clinically significant problem in patient blood culture testing. The study was designed to evaluate the impact of a device on blood culture contamination rates and false-positive central-line-associated bloodstream infections.

**Methods.** The study was designed to evaluate the impact of a device on blood culture contamination rates and false-positive central-line-associated bloodstream infections. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of a device on blood culture contamination rates and false-positive central-line-associated bloodstream infections.

**Results.** The study was designed to evaluate the impact of a device on blood culture contamination rates and false-positive central-line-associated bloodstream infections. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of a device on blood culture contamination rates and false-positive central-line-associated bloodstream infections.

**Conclusion.** The use of a device significantly reduced blood culture contamination rates and false-positive central-line-associated bloodstream infections. The study was conducted in a tertiary care hospital. The study was designed to evaluate the impact of a device on blood culture contamination rates and false-positive central-line-associated bloodstream infections.

# Reduction in Blood Culture Contamination Through the Use of Initial Specimen Diversion Device



Researchers calculated the study institution would save **\$1.8M/year** With ISDD

# Getting to Zero



**TITLE:** Getting to Zero: Impact of a Device ISDD to Reduce Blood Culture Contamination and False-Positive Central Line-Associated Bloodstream Infections

**CONFERENCE** *IDWeek 2020 and PACCARB 2021*

**INSTITUTE:** Stanford Health Care


**AUTHORS:** Lucy Tompkins, MD, PhD, et al

**DESIGN:** Single-center, prospective, controlled study  
March 2019–January 2020 (10-months)

**METHOD:** Blood cultures were obtained **hospital-wide** by **Phlebotomy team** using the ISDD compared to standard method.

**RESULTS:** **100%** reduction in blood culture contamination  
ISDD: **0.0% (0/11,202)** contamination rate  
Standard method: **2.3% (111/4,759)** contamination rate

**12-Fold** decrease in NHSN/CMS reportable **False-Positive CLABSIs**  
ISDD: **1**  
Standard method: **12**  
**SIR** fell by **30-50%** when contaminants were removed



# Peer-Reviewed Publication



**TITLE:** Effectiveness of a Novel Blood Culture Collection System in Reducing Blood Culture Contamination Rates in the ED

**PUBLICATION:** *Journal of Emergency Nursing (2018)*

**INSTITUTE:** Lee Health (multi-center trial n=4)


**AUTHORS:** Mary Bell, MSN, RN, CEN, et al

**AFFILIATIONS:** Department of Emergency Medicine

**METHOD:** Blood cultures contamination rates with ISDD collected via **peripheral IV start** and **venipuncture** were compared with historical rates via standard method.

**RESULTS:** **83%** reduction in contamination with ISDD  
ISDD: **0.6%** (38/6,293) contamination rate (**P=0.0001**)  
Standard procedure: **3.5%** (1,246/35,392) contaminate rate

**SUMMARY:** Prevented **184** false-positive events  
**86%** of ISDD draws are via PIV starts  
Cost savings of **\$641,792** during a 7-month trial period



# Peer-Reviewed Publication

**TITLE:** Initial Specimen Diversion Device<sup>®</sup> Reduces Blood Culture Contamination and Vancomycin Use in Academic Medical Center



**PUBLICATION:** *The Journal of Hospital Infection*

**INSTITUTE:** Brooke Army Medical Center

**AUTHORS:** Lindsey Nielsen, PhD, ASCP(M,MB), et al


**AFFILIATIONS:** Pathology, Lab Services, Emergency Medicine, and Infectious Disease

**DESIGN:** Single-center, retrospective, non-randomized

























**METHOD:** Comparison of Vancomycin DOT before/after interventions to reduce pathogen detection time (NAAT) and blood culture contamination ISDD in the ED. Hospital-wide vancomycin DOT collected through EMR.

**RESULTS:** Vancomycin DOT per 1,000 patient days decreased 18% (47.2 +/-5.4 to 38.5 +/-13.3) after implementation of NAAT. ISDD resulted in a significant incremental decrease in vancomycin DOT by 31% (38.5 +/-13.3 to 26.4 +/- 6.2)

**SUMMARY:** Blood culture contamination rate was not significantly altered after implementation of rapid molecular PCR identification method. Reducing contamination with ISDD contributed to a significant reduction in unnecessary antibiotic therapy.



# Peer-Reviewed Published Studies and Clinical Study Presentations at Major Medical Conferences

#	Institution	Publication or Conference Presentation	Date	Duration	Baseline or Control Rate	ISDD Rate	BCC Reduction	Ann. Savings
1	Stanford Health Care	IDSA – IDWeek / PACCARB/ ICHE 	2020/21	10 months	2.3%	0.0%	100%	NR
2	Central Texas VA Medical Center	Journal of Emergency Nursing  	2021	5 months	2.2%	0.0%	100%	NR
3	Univ. of Nebraska Medical Center	Clinical Infectious Diseases 	2017	12 months	1.8%	0.2%	88%	\$1,800,000
4	Baylor Scott & White Med Ctr.	Emergency Nurses Association (ENA) 	2021	4 months	3.2%	0.2%	93%	NR
5	Kern Medical Center	APIC - Submitted for publication 	2021	18 months	2.4%	0.4%	83%	NR
6	Lee Health System (4 sites)	Journal of Emergency Nursing  	2018	7 months	3.5%	0.6%	83%	\$1,100,000
7	Brooke Army Medical Center	Journal of Hospital Infection  	2021	6 months	6.6%	0.7%	90%	NR
8	Medical Univ. of South Carolina	Institute for Healthcare Improvement (IHI) 	2016	8 months	4.2%	0.6%	86%	NR
9	Rush University Medical Center	IDSA - IDWeek	2017	3 months	4.3%	0.6%	86%	NR
10	Inova Fairfax Hospital	Emergency Nurses Association (ENA)  	2019	12 months	4.4%	0.8%	82%	\$932,000
11	WVU United Hospital Center	American Journal for Medical Quality  	2021	8 months	4.1%	0.8%	81%	NR
12	SCL St. Mary's Medical Center	American Organization for Nursing Leadership (AONL) 	2020	6 months	3.3%	0.8%	76%	NR
13	Beebe Healthcare	American Society for Microbiology (ASM)	2018	4 months	3.0%	0.8%	75%	NR
14	Medical Univ. of South Carolina	Institute for Healthcare Improvement (IHI) 	2017	20 months	4.6%	0.9%	80%	\$447,000
15	Ascension Via Christi (3 sites)	Society of Hospital Epidemiology of America (SHEA) 	2021	3 months	4.3%	0.9%	79%	NR
16	VA Houston	Emergency Nurses Association (ENA) 	2018	7 months	5.5%	0.9%	83%	NR
17	Shaare Zedek Medical Center	American Journal of Infection Control  	2019	6 months	5.2%	1.0%	81%	NR
18	Brooke Army Medical Center	Journal of Hospital Infection 	2021	14 months		31% reduction in vancomycin DOT		
19	University of Houston	Journal of Clinical Microbiology 	2019	ISDD can save the hospital <b>2.0 bed days</b> and <b>\$4,739 per false-positive</b> blood culture event				
20	Mass General/ Harvard/ WingTech	Journal of Hospital Infection 	2019	ISDD can save the hospital <b>2.4 bed days</b> , <b>\$4,817 per false-positive</b> blood culture event and <b>\$1.9M annually and prevent 34 HACs including 3 C.diff</b>				



National Peer-Reviewed Publication



Best Evidence-Based Project



Peripheral IV Start






# CLSI M47 2<sup>nd</sup> Edition 2022

## *Principles and Procedures for Blood Cultures*


“

Even when optimal blood specimen collection protocols are used, completely eliminating blood culture contamination may be impossible. However, laboratories should still be able to achieve blood culture contamination rates *substantially lower than 3%*. When best practices are followed, a *target contamination rate of 1%* is achievable.”



- Six studies were cited within the CLSI guidelines regarding the clinical impact of self-contained devices that achieve initial specimen diversion on reducing contamination rates
- ALL studies examined the clinical efficacy of ISDD with diversion of >1ML and/or referenced said ISDD specific datasets and reported a sustained 1% or lower contamination rate.

# Evidence-Based Guidelines to Reduce Blood Culture Contamination



**CLINICAL PRACTICE GUIDELINE:**

**Prevention of Blood Culture Contamination**

Which preanalytic variables related to peripheral venous specimen collection and transportation decrease blood culture contamination?

Supplement to January/February 2021 | Volume 44 | Number 51 | 1041-1533-1458 | www.journalofinfusionnursing.com

**Journal of Infusion Nursing**

The Official Publication of the Infusion Nurses Society

**Infusion Therapy Standards of Practice**

8th Edition

Lippincott | Wolters Kluwer

**M47 Principles and Procedures for Blood Cultures**

2nd Edition

This guideline includes recommendations for collecting, transporting, and processing specimens for blood culture, as well as procedures for recovering pathogens from the blood of patients with suspected bacteremia or fungemia.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

**Blood Culture Contamination: An Overview for Infection Control and Antibiotic Stewardship Programs Working with the Clinical Laboratory**

**Purpose**  
Blood culture contamination can compromise quality of care and lead to unnecessary antibiotic exposure and prolonged length of hospitalization. Microbiology laboratories typically track blood culture contamination rates and can provide data to assist in reducing contamination rates. Infection control programs and microbiology laboratories might participate in designing and implementing interventions to decrease contamination rates, and antibiotic stewardship programs could also be engaged to optimize multidisciplinary quality improvement efforts to decrease blood culture contamination and improve the collection of blood culture specimens.

**Background**  
Blood cultures are important diagnostic tools for identifying the pathogen(s) responsible for a patient's infection. This is especially true of patients with suspected sepsis or septic shock and for patients with suspected infective endocarditis (IE). When indicated, blood cultures should be obtained prior to starting antimicrobial therapy. A conventional blood culture set consists of an aerobic and an anaerobic bottle. For adults, 20-40 mL of blood per vial/port (depending on the instrument manufacturer) is recommended and may require <2 bottles depending on the system. At least two blood culture sets should be obtained within a few hours of each other via peripheral venipuncture when obtaining blood cultures for a total volume of 40-80 mL of blood to optimize detection of pathogens. The College of American Pathologists laboratory accreditation program states that clinical laboratories have a written policy and procedure for monitoring blood cultures from adults for adequate volume and provide feedback on the results to the collector. Moreover, the monitoring and reporting of blood culture contamination rates is a laboratory quality best practice. Because blood is a normally sterile body site, positive blood cultures with a known pathogen have a generally overall high positive predictive value for infection. However, blood culture contamination is a significant problem. In the era of modern blood culturing techniques, virtually all blood culture contamination occurs during collection; the source of contamination is usually the patient's skin or the hub or cannula of an indwelling catheter (i.e., when an existing catheter is used to obtain the specimen). Frequent causes include poor collection technique and insufficient skin disinfection. Typical organisms include coagulase-negative staphylococci, Corynebacterium spp., Bacillus spp., other than Bacillus anthracis, Micrococcus spp., and Clostridium species among others. Consequences include unnecessary antibiotic exposure with the potential for downstream unintended consequences (e.g., possible allergic reactions and Clostridium difficile infection). Other possible consequences include the unnecessary removal of intravenous catheters or other devices, an increased length of stay, and increased costs. One study found that the average length of stay was 2 days longer in patients with contaminated blood cultures compared to patients with negative cultures. That same study found that direct and indirect hospital costs of a contaminated blood culture were \$12,204 compared to \$8,286 for a negative blood culture (savings of \$4,918 for preventing a contaminated blood culture).

U.S. Department of Health and Human Services  
Centers for Disease Control and Prevention

**Guidance to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)**

**Keywords:** specimen quality, diagnostic accuracy, physician lab interface, optimizing results, clinical relevance.

Antimicrobial stewardship programs (ASPs) need to optimize antibiotic use, reduce selection for antimicrobial-resistant microorganisms, and improve patient outcomes. Rapid and accurate diagnosis is essential to optimal antibiotic use. Because diagnostic testing plays a significant role in diagnosing patients, it has one of the strongest influences on clinician antibiotic prescribing behaviors. Diagnostic stewardship, consequently, has emerged to improve diagnostic testing and to limit inappropriate, antimicrobial stewardship and diagnostic stewardship share common goals and are synergistic when used together. Although ASP requires a relationship with clinicians and focuses on person-to-person communication, diagnostic stewardship centers on a relationship with the laboratory and handling testing changes to laboratory processes and the electronic health record. Here, we discuss how diagnostic stewardship can optimize the "Test Moments of Antibiotic Decision Making" created by the Agency for Healthcare Research and Quality and work synergistically with ASP.

**SHEA Position Paper**

**Improving antimicrobial use through better diagnosis: The relationship between diagnostic stewardship and antimicrobial stewardship**

Tsun Sheng N. Ku MD<sup>1,2</sup>, Mayer AJ. Hagan MD<sup>3,4</sup>, James A. Newton MD<sup>5,6</sup>, Marie H. Wilson MSN, RN, CIC<sup>7</sup>, Elizabeth Horvath PhD, MBA, RN, CIC<sup>8,9</sup>, Mary K. Hayden MD<sup>10</sup>, Kevin Horvath MD, PhD<sup>11</sup>, James I. Kligman PhD<sup>12</sup>, Daniel J. Diekema MD<sup>13,14</sup>, Daniel J. Morgan MD<sup>15,16</sup>, Costi D. Sifri MD<sup>17</sup> and Valerie M. Vaughn MD, MS<sup>18</sup>

**Executive summary**  
Antimicrobial stewardship programs (ASPs) need to optimize antibiotic use, reduce selection for antimicrobial-resistant microorganisms, and improve patient outcomes. Rapid and accurate diagnosis is essential to optimal antibiotic use. Because diagnostic testing plays a significant role in diagnosing patients, it has one of the strongest influences on clinician antibiotic prescribing behaviors. Diagnostic stewardship, consequently, has emerged to improve diagnostic testing and to limit inappropriate, antimicrobial stewardship and diagnostic stewardship share common goals and are synergistic when used together. Although ASP requires a relationship with clinicians and focuses on person-to-person communication, diagnostic stewardship centers on a relationship with the laboratory and handling testing changes to laboratory processes and the electronic health record. Here, we discuss how diagnostic stewardship can optimize the "Test Moments of Antibiotic Decision Making" created by the Agency for Healthcare Research and Quality and work synergistically with ASP.

1.0–2.0 mL diversion volume

Diversion Devices

1.0 mL diversion volume  
1% goal for blood culture contamination  
(GP41 ED7 2017)  
(M47 ED2 2022)

1% goal for blood culture contamination  
Diversion Devices  
(CDC Guidelines, 2022)

"In addition, products are available that allow diversion and discard of the first few milliliters of blood that are most likely to contain skin contaminants. Target rate of 1%"

Blood culture diversion technique or devices  
SHEA Position Statement  
ICHE 2023

# 2024 ASM/SHEA Guidelines for Blood Culture Collection



## American Society for Microbiology evidence-based laboratory medicine practice guidelines to reduce blood culture contamination rates: a systematic review and meta-analysis

Robert L. Sautter,<sup>1</sup> James Scott Parrott,<sup>2,3,4,5</sup> Irving Nachamkin,<sup>6</sup> Christen Diel,<sup>7</sup> Ryan J. Tom,<sup>8,9</sup> April M. Bobenchik,<sup>10</sup> Judith Young Bradford,<sup>11</sup> Peter Gilligan,<sup>12</sup> Diane C. Halstead,<sup>13</sup> P. Rocco LaSala,<sup>14</sup> A. Brian Mochon,<sup>15,16</sup> Joel E. Mortensen,<sup>17</sup> Lindsay Boyce,<sup>18</sup> Vickie Baselski<sup>19</sup>

**AUTHOR AFFILIATIONS** See affiliation list on p. 32.

SUMMARY	2
INTRODUCTION	3
METHODS	6
Information sources	6
Search strategy	6
Selection process	6
Data collection	7
Data items	7
Study risk of bias assessment	7
Strength of evidence	7
Statistical methods	9
Effect measures	9
Synthesis eligibility, missing data, and data estimation	9
Statistical methods	9
Diagnostics and reporting bias	10
Heterogeneity and sensitivity analysis	10
DESCRIPTION OF STUDIES	11
Included studies	11
Excluded studies	11
Risk of bias in included studies	11
Before–after designs	11
Cohort design	12
Controlled interventions	13
RECOMMENDATIONS	14
Chlorhexidine	14
Recommendation	14
Literature review summary	14
Evidence summary	15
Diversion devices	16
Recommendation	16
Literature review summary	16
Evidence summary	17
Phlebotomy teams	17
Recommendation	17
Literature review summary	17
Evidence summary	17
Sterile techniques	18
Recommendation	18
Literature review summary	18
Evidence summary	18
Education and training	18
Recommendation	18
Literature review summary	19
Multidisciplinary teams	20
ADDITIONAL OUTCOMES	20
EVIDENCE OF PUBLICATION BIAS	21

**Editor** Graeme N. Forrest, Rush University Medical Center, Chicago, Illinois, USA

**Peer Reviewer** Karen M. Frank, National Institutes of Health, Bethesda, Maryland, USA


Address correspondence to Robert L. Sautter, Sautterfamily@hotmail.com, or Irving Nachamkin, nachamki@perimed.cne.upenn.edu.

The authors declare no conflict of interest.

See the funding table on p. 32.

Published 4 November 2024

Copyright © 2024 Sautter et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.



“There was a range of blood volume discarded in the six studies from 1 to 7 mL of discard per draw. While small volume discards (<2 mL) are likely to cause little harm to patients, discarding larger volumes of blood (e.g., 7 mL in the Syed et al. study) might contribute to the development of iatrogenic anemia in patients with prolonged hospital stays and frequent BCs”

# Major steps toward CMS adoption of CDC/NQF Blood Culture Quality Measure



U.S. Department of  
Health and Human Services  
Centers for Disease  
Control and Prevention



NATIONAL  
QUALITY FORUM

**CDC-initiated** blood culture quality measure developed and submitted to NQF, April 2022

Published evidence-based guidelines including Diversion Devices and citing a **1% goal** for blood culture contamination, 2022

NQF Consensus Standards Approval Committee (CSAC) formally **endorsed** the **CDC's** blood culture quality measure in December 2022

**Finding:** On a national scale, BCC results in nearly 1,000,000 extra hospital days, 200,000 courses of unneeded antibiotics and over \$1 billion in excess costs, Up to 40% of patients with contaminated blood cultures are started on antibiotics resulting in nephrotoxicity, CDI, allergic reaction, AMR, ELOS, HAI/HAC, Costs, and unnecessary utilization of resources.

# Hospital-Onset Bacteremia & Fungemia (HOB) Quality Measure

**Blood Culture Contamination will be an NHSN/CMS/CDC reportable quality metric, part of HOB composite score**  
*Hospital is **accountable to prove** that the patient had a **BSI** prior to day four*

Patient Example	Blood Culture Drawn ED or On Admission and Through Day 3	Additional Blood Culture Drawn On Day 4 or Later After Admission	HOB
Patient #1	True Positive	True Positive	No
Patient #2	True Negative	True Positive	Yes
Patient #3	False Negative	True Positive	Yes
Patient #4	False Positive (common commensal)	True Positive	Yes
Patient #5	False Positive (common commensal / skin residing organism)	False Positive (non-common commensal / pathogenic organism from skin) (I.e. false positive MRSA, CLABSI, BSI)	Yes

34% of HOB did not meet criteria due to positive blood culture on admission or up to day 3<sup>1</sup>  
 AJIC study: the most common cause of preventable HOB is blood culture contamination; non common commensal organisms

**Accurate blood cultures will be more critical than ever to mitigate a HOB**

<sup>1</sup>Yu KC, et al. (2022). Hospital-onset bacteremia and fungemia: An evaluation of predictors and feasibility of benchmarking comparing two risk-adjusted models among 267 hospitals. Infection Control & Hospital Epidemiology, <https://doi.org/10.1017/ice.2022.211>  
 Am J Infect Control 2024 Feb;52(2):195-199. doi: 10.1016/j.ajic.2023.06.002. Epub 2023 Jun 7.

# Broadened Surveillance Definition of BSI Passed by NQF 2.23



## HOB

### (Hospital Onset Blood Stream Infection)

**Purpose:** Surveillance for broader reduction of BSI regardless of organism (eg. MRSA) or association with Device (eg. CLABSI)

**Definitions:** HOB Blood culture collected on day 4 or later with pathogenic bacteria or fungi

Serious: 24% mortality compared to patients without HOB.

Higher cost \$44K vs \$25 K

Common Up to 115,000 cases or 0.34% of all admissions

Preventability: Many cases are preventable

**Timeline: Voluntary Reporting Now**

“The names of the patients whose lives we save can never be known. Our contribution will be what did not happen to them. And, though they are unknown, we will know that mothers and fathers are at graduations and weddings they would have missed, and that grandchildren will know grandparents they might never have known, and holidays will be taken, and work completed, and books read, and symphonies heard, and gardens tended that, without our work, would never have been.”

Donald Berwick, MD, Founder of IHI

**THANK YOU**

**FOR ALL OF YOUR WORK ON BEHALF OF PATIENT QUALITY OUTCOMES!**